Core Viewpoint - The domestic new drug sector is entering a new growth cycle, highlighting the global value realization of Chinese innovative drugs [1] Group 1: Market Trends - By 2025, the number and scale of License out transactions are expected to reach record highs, demonstrating the global competitiveness of domestic new drugs [1] - The successful advancement of overseas clinical trials is crucial for realizing global value, indicating that business development (BD) is just the starting point [1] Group 2: Industry Participation - Several domestic new drugs are becoming flagship products for multinational corporations (MNCs), showcasing the deep involvement of Chinese pharmaceutical companies in the global medical ecosystem [1] - There is potential for a group of Chinese innovative pharmaceutical companies to grow with a global perspective and international operational capabilities [1]